🔴 Aquestive Therapeutics is trading 6.2% down; reason remains unclear

Aquestive Therapeutics is trading at $4.33, 6.2% down on October 15, 2026; available reporting does not identify a cause for the intraday decline.

• The company announced FDA acceptance of Anaphylm’s NDA resubmission and a March 16, 2027 PDUFA date, a significant regulatory update, but reporting does not identify it as the cause.
• Major indexes were uneven and biotech rose 2.20%; neither clearly accounts for the drop. No specific company-related negative catalyst was found.